Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+

moderators

Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022
The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...

katg

I had not read this before. After having pancytopenia from 12 rounds of two chemos and one round of AC, i was given a different olarib pill. A cousin of Lynparza. That made my blood numbers dive again. Interesting, I went on Lynparza 6 months later for 1 year at a lower dose then . BRCA2 and Her 2+. Was i already developing MDS?